Cerebral Oximetry Monitoring Market

The growing geriatric population is driving the market growth

The primary drivers of the market's growth are the expanding geriatric population and the rising incidence of ailments including cardiovascular and neurological problems. The adoption of the western lifestyle, heavy smoking, alcohol consumption, and physical inactivity led to an estimated 697,000 Americans having coronary artery disease (CAD) in 2020, according to the centres for disease control and prevention (CDC). The demand for cerebral oximetry monitoring equipment to perform safe CAD surgery is anticipated to increase as the number of CAD cases rises.

It has been noted that regulatory organisations like the U.S. FDA and EMA approve new cerebral oximeter devices, providing market participants with a business opportunity. As cerebral oximeters are one of the most crucial tools used to track the level of oxygen in the brain, the prevalence of neurological illnesses also increases the need for these instruments. Thus, it is projected that throughout the forecast period, market growth would be driven by the increasing acceptance of these devices and the device industry's ongoing evolution.

It is anticipated that the market would expand as a result of the combined usage of cerebral oximeters and other technologies. For instance, Medtronic integrated two continuous monitoring technologies into the CARESCAPE platform of G.E. Healthcare in June 2022, enabling physicians to personalise care. The ICU and surgical care will use the Microstream capnography and INVOS regional oximetry technology. The FDA has approved the integration, and the CE Mark has been obtained. The whole set of Medtronic patient monitoring technologies is now complete and accessible on the CARESCAPE platform. Additionally, the system features FlexAcuity from G.E.

Healthcare, which enables physicians to select care alternatives depending on patient acuity requirements and identify deterioration early. Worldwide clinicians now have more alternatives for patient treatment thanks to this connection. Thus, driving the Cerebral Oximetry Monitoring market revenue.

The Global Cerebral Oximetry Monitoring Market Industry is projected to experience substantial growth over the coming years. With an estimated market size of 0.12 USD Billion in 2024, the industry is expected to expand significantly, reaching 0.23 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate of 6.23% from 2025 to 2035. Factors contributing to this expansion include technological advancements, increasing prevalence of neurological disorders, and rising awareness of the benefits of cerebral oximetry monitoring. As these trends continue to evolve, the market is likely to witness a robust increase in demand for cerebral oximetry devices.

There is an increasing awareness among healthcare professionals regarding the benefits of cerebral oximetry monitoring, which is driving the Global Cerebral Oximetry Monitoring Market Industry. This awareness is largely due to educational initiatives and clinical studies demonstrating the advantages of monitoring cerebral oxygenation during surgeries and critical care. As clinicians recognize the potential for improved patient outcomes, the demand for cerebral oximetry devices is likely to rise. This trend is expected to contribute to the market's growth, with projections indicating an increase to 0.23 USD Billion by 2035, as more healthcare facilities adopt these monitoring technologies.

The rising incidence of neurological disorders globally is a primary driver for the Global Cerebral Oximetry Monitoring Market Industry. Conditions such as stroke, traumatic brain injury, and neurodegenerative diseases necessitate effective monitoring solutions. As the global population ages, the demand for cerebral oximetry monitoring is expected to increase significantly. In 2024, the market is projected to reach 0.12 USD Billion, reflecting the urgent need for advanced monitoring technologies in clinical settings. This trend is likely to continue, with the market anticipated to grow as healthcare providers seek to enhance patient outcomes through improved cerebral oxygenation assessment.

Technological innovations in cerebral oximetry devices are propelling the Global Cerebral Oximetry Monitoring Market Industry forward. Recent advancements include the development of portable and non-invasive monitoring systems that provide real-time data on cerebral oxygen levels. These innovations enhance the accuracy and reliability of monitoring, making it easier for healthcare professionals to make informed decisions. As a result, the market is expected to witness a compound annual growth rate of 6.23% from 2025 to 2035. The integration of artificial intelligence and machine learning into these devices further supports their adoption, as they offer predictive analytics that can improve patient management.

The shift towards non-invasive monitoring techniques is a significant factor influencing the Global Cerebral Oximetry Monitoring Market Industry. Non-invasive methods are preferred due to their ability to minimize patient discomfort and reduce the risk of complications associated with invasive procedures. As healthcare providers increasingly prioritize patient safety and comfort, the demand for non-invasive cerebral oximetry devices is expected to grow. This trend aligns with the overall movement towards patient-centered care, which emphasizes the importance of monitoring without compromising patient well-being. Consequently, the market is likely to expand as more facilities adopt these innovative solutions.

The expansion of healthcare infrastructure in emerging markets is a crucial driver for the Global Cerebral Oximetry Monitoring Market Industry. As countries invest in healthcare facilities and technologies, the demand for advanced monitoring solutions, including cerebral oximetry, is expected to rise. This growth is particularly evident in regions with increasing healthcare expenditures and a focus on improving patient care. Emerging markets are likely to adopt cerebral oximetry monitoring as part of their efforts to enhance surgical outcomes and critical care management. This trend may lead to a substantial increase in market size, supporting the overall growth trajectory of the industry.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Cerebral Oximetry Monitoring Market dominated this market in 2022 (45.80%). This can be attributable to the presence and offerings of significant players in the area. To monitor cerebral desaturation during cardiac surgery, oximeter devices including the INVOS System, ForeSight System, EQUANOX, and Root with O3 are commonly supplied in the United States by Medtronic, Edwards Lifesciences Corporation, Nonin, and Masimo. Further, the U.S.

Cerebral Oximetry Monitoring market held the largest market share, and the Canada Cerebral Oximetry Monitoring market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  CEREBRAL OXIMETRY MONITORING MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Cerebral Oximetry Monitoring market accounted for the healthy market share in 2022. A desk-bound lifestyle devoid of exercise, a poor diet, anxiety, and stress that result in chronic illnesses like diabetes and obesity, as well as an increase in the prevalence of numerous cardiovascular diseases (CVD), are the main factors contributing to the growth of cerebral oximeters. Further, the German Cerebral Oximetry Monitoring market held the largest market share, and the U.K Cerebral Oximetry Monitoring market was the fastest growing market in the European region

The Asia Pacific Cerebral Oximetry Monitoring market is expected to register significant growth from 2024 to 2032. The region's ageing population, rising disease rates, and rising per capita disposable incomes are the main market-drivers in the area. Numerous studies have shown that older adults have a high risk of cardiovascular disease (CVD) because of their high comorbidity rates. According to a projection from the National Statistical Office, there would be 194 million senior people in the country by the end of 2021, up from 138 million in 2021.

Moreover, China’s Cerebral Oximetry Monitoring market held the largest market share, and the Indian Cerebral Oximetry Monitoring market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Cerebral Oximetry Monitoring market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cerebral Oximetry Monitoring Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Cerebral Oximetry Monitoring Industry to benefit clients and increase the market sector. In recent years, the Cerebral Oximetry Monitoring Industry has offered some of the most significant advantages to medicine. Major players in the Cerebral Oximetry Monitoring market, including Boston Scientific, Omron Healthcare, Welch Allyn, Honeywell Life Sciences, Natus Medical, Mindray Medical, Edwards Lifesciences, GE Healthcare, Masimo, Philips Healthcare, and Medtronic, are attempting to increase market demand by investing in research and development operations.

A medical technology firm called Medtronic Plc (Medtronic), originally known as Medtronic Inc., creates, develops, produces, and sells a variety of medical products. It provides products for the treatment of conditions such heart valve issues, heart failure, aortic, peripheral vascular, venous renal, and neurological problems, as well as spine and musculoskeletal issues, ear, nose, and throat conditions. Additionally, it offers biologic solutions for the dental and orthopaedic markets. In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it provides its products to hospitals, third-party healthcare providers, clinics, institutions, including governmental health care programmes, distributors, and group purchasing organisations.

The headquarters of Medtronic are in Dublin, Ireland. The INVOS 7100 cerebral/somatic oximetry device from Medtronic PLC received FDA 510(k) clearance for paediatric indications in December 2021. Paediatric clinicians who treat neonates, preterm infants, children, and other patients can make quick judgements on ventilation, hemodynamic management, and resuscitation with the use of the INVOS system.

A medical technology business called Masimo Corp. (Masimo) creates, produces, and sells non-invasive patient monitoring systems, medical equipment, and sensors to enhance patient care. The company's proprietary technologies include the rainbow SET platform and signal extraction technology (SET), which both assist in the detection of life-threatening occurrences. Patients monitors, pulse oximeters, central monitoring systems, specialised sensors, circuit boards, remote alerts, and monitoring solutions are some of its main products.

Additionally, the business sells its goods directly to consumers as well as through a network of distributors and original equipment manufacturers that serve hospitals, long-term care facilities, veterinarian offices, emergency medical service providers, and home care providers. The corporation has operations in Australia, Asia, the Middle East, Europe, North and South America, and Africa. United States-based Masimo is based in Irvine, California. O3 Regional Oximetry was approved by the FDA for expanded usage in August 2020, according to Masimo.

This includes monitoring somatic tissue oxygenation saturation in all patient populations as well as relative changes in haemoglobin, oxyhemoglobin, and deoxyhemoglobin in adult brains.